CRYSTALLINE FORMS OF A COMPOUND FOR THE TARGETED DEGRADATION OF ESTROGEN RECEPTOR

The present disclosure relates to polymorphic forms of (S)-3-(5-(4-((1-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, (Compound A), methods of making these polymorphic forms, and compositions co...

Full description

Saved in:
Bibliographic Details
Main Authors REECE, Hayley, BOULTON, Katharine Victoria, CHEN, Chungpin Herman, HASKELL, III
Format Patent
LanguageEnglish
French
Published 17.03.2022
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present disclosure relates to polymorphic forms of (S)-3-(5-(4-((1-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, (Compound A), methods of making these polymorphic forms, and compositions comprising these polymorphic forms. These polymorphic forms are useful in the treatment of various diseases, including, for example, breast cancer. La présente divulgation concerne des formes polymorphes de (S)-3-(5-(4-((1-(4-((1R,2S)-6-hydroxy-2-phényl-1,2,3,4-tétrahydronaphtalén-1-yl)phényl)pipéridin-4-yl)méthyl)pipérazin-1-yl)-1-oxoisoindolin-2-yl)pipéridine-2,6-dione, (composé A), des procédés de fabrication de ces formes polymorphes, et des compositions comprenant ces formes polymorphes. Ces formes polymorphes sont utiles dans le traitement de diverses maladies, notamment, par exemple, le cancer du sein.
Bibliography:Application Number: WO2021US50046